Found 19 Prostate Disorders trials
A listing of Prostate Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Study Evaluating the Safety and tolerability of AMG 757 and determine the maximum tolerated dose (DeLLpro-300)
To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
18F-FluorThanatrace positron emission tomography (PET/CT) in Patients with Metastatic Prostate Cancer
The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to take computerized pictures of places in the body where prostate cancer has spread (metastasized). The pictures will be taken before, and optionally after treatment. 18F-FTT is a drug used …
Mild Hypofractionation using Proton Therapy or IMRT for Low- and Intermediate-Risk Prostate Cancer
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of low or intermediate risk of prostate cancer presenting for definitive radiation treatment with either proton radiotherapy or IMRT. We propose to employ a hypofractionated strategy …
A Study of REGN5678 (anti-PSMAxCD28) with Cemiplimab (anti-PD-1) in Patients with Metastatic Prostate Cancer
This study involves research and is conducted to determine the safety, tolerability (how 6 your body reacts to the drug) and effectiveness of a study drug called REGN5678 which 7 will be given alone first and then be given in combination with cemiplimab.
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in …
SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 multi-institution randomized prospective clinical trial evaluating the impact of cytoreductive radical prostatectomy combined with best systemic therapy on oncologic and quality of life outcomes in men with newly diagnosed metastatic prostate cancer
This study investigates the effects of adding cytoreductive radical prostatectomy (CRP) to the standard treatment, best systemic therapy (BST), for metastatic prostate cancer (mPCa). CRP removes as much of the cancer as possible (and radical prostatectomy removes only prostate) while BST uses drugs toxic to cancer cells: chemotherapy and androgen …
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
This is a research study for those with metastatic castration-resistant prostate cancer (mCRPC) that has progressed following treatment with prior therapy and cannot receive or refuse to receive chemotherapy. The purpose of this research study is to learn about the safety and effectiveness of 177Lu PNT2002, an investigational agent being …
A multicenter randomized controlled phase 2 study: Efficacy and safety of I-131-1095 radiotherapy in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients who are 18F-DCFPyL prostate specific membrane antigen (PSMA)-avid chemotherapy-na ve and progressed on abiraterone (ARROW)
A multicenter, open label, randomized phase 2 study of I-131-1095 radiotherapy (less than or equal to 100 mCi/dose) every 8 weeks for up to 4 doses in combination with enzalutamide compared to enzalutamide alone in patients with progressive mCRPC. Patients must have documented progression on abiraterone and be indicated for …
1 - 10 of 19
- 1
- 2
Please choose between Voice or SMS based delivery of verification code
or